View Older Stories View More Recent Stories

Jun 14, 2024 07:30AM Cogent Biosciences (COGT) Announces Additional Data from Part 1 of SUMMIT Trial Evaluating Bezuclastinib
Jun 14, 2024 07:30AM Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
May 23, 2024 05:05PM Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
May 23, 2024 05:01PM Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST
May 7, 2024 08:00AM Cogent Biosciences Reports First Quarter 2024 Financial Results
Apr 9, 2024 09:00AM Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Feb 26, 2024 08:00AM Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Feb 22, 2024 02:30PM Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Feb 22, 2024 02:30PM Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
Feb 5, 2024 09:00AM Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Jan 9, 2024 08:00AM Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
Jan 2, 2024 08:00AM Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 11, 2023 07:55AM Cogent Biosciences (COGT) Reports Positive Data from Ongoing Phase 2 APEX Trial of Bezuclastinib
Dec 11, 2023 07:55AM Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Dec 11, 2023 04:00AM Cogent Biosciences (COGT) Reports Positive Initial Data from Phase 2 SUMMIT Trial of Bezuclastinib
Dec 9, 2023 01:30PM Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Dec 7, 2023 09:05AM Cogent Biosciences (COGT) Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs
Dec 7, 2023 09:00AM Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
Dec 4, 2023 08:00AM Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
Nov 29, 2023 08:00AM Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
Nov 2, 2023 09:00AM Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
Oct 14, 2023 12:30PM Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Aug 8, 2023 08:00AM Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Jun 7, 2023 09:00AM Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
Jun 5, 2023 05:56AM Cogent Biosciences (COGT) Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial of Bezuclastinib with Sunitinib
Jun 3, 2023 02:15PM Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
May 23, 2023 08:00AM Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
May 9, 2023 08:00AM Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
Apr 17, 2023 09:01AM Cogent Biosciences (COGT) Presents Preclinical Data
Apr 17, 2023 09:00AM Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastini
Apr 12, 2023 08:00AM Cogent Biosciences Announces Participation at Upcoming Investor Conferences
Mar 14, 2023 08:00AM Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Feb 1, 2023 08:00AM Cogent Biosciences Announces Participation at Upcoming Investor Conferences
Jan 9, 2023 08:19AM Cogent Biosciences (COGT) Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Jan 9, 2023 08:00AM Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Jan 5, 2023 08:00AM Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022 06:49AM Cogent Biosciences (COGT) announces positive data update from Phase 2 APEX trail of bezuclastinib in AdvSM
Dec 11, 2022 05:30PM Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Dec 5, 2022 08:00AM Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
Nov 14, 2022 07:00AM Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Aug 9, 2022 07:00AM Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Jun 10, 2022 07:01AM Cogent Biosciences (COGT) Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis
Jun 10, 2022 07:00AM Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Jun 6, 2022 10:15AM Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
Jun 2, 2022 08:00AM Cogent Biosciences Announces Annual Meeting of Stockholders
May 12, 2022 10:00AM Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
May 10, 2022 07:00AM Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 6, 2022 08:00AM Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
Apr 11, 2022 07:00AM Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
Mar 29, 2022 07:00AM Cogent Biosciences to Host Virtual R&D Investor Event
View More Recent Stories View Older Stories